Status
Conditions
Treatments
About
This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.
Full description
The proposed study aims to perform a split cohort study where each patient's cohort of fertilized zygotes, (two pronuclei or 2PNs) is split into two groups and randomized, thus allowing each patient to serve as their own control and decreasing confounding variables. Half of the cohort will proceed with the current standard of day 3 or cleavage assisted hatching and the other half of the cohort will receive the sequential hatching and trophectoderm biopsy procedure at the blastocyst stage of embryo development.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for participants:
Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo
<4 2PNs prior to randomization
Female partners age <42 years old at start of VOR cycle
Normal ovarian reserve:
BMI <38
Patients who desire to transfer the best quality embryo for their embryo transfer.
Exclusion Criteria for participants:
Primary purpose
Allocation
Interventional model
Masking
75 participants in 2 patient groups
Loading...
Central trial contact
Caroline Zuckerman, BS, RN; Christine V Whitehead, MS, BSN, RN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal